| Abstract: |
Two distinct regions or epitope clusters of human immunodeficiency virus type 1 (HIV-1) gp120 have been shown to elicit neutralizing antibodies: the V3 loop and the CD4-binding site. We have isolated neutralizing human monoclonal antibodies (HuMAbs) against conserved epitopes in both of these regions. In this study, we demonstrate that an equimolar mixture of two of these HuMAbs, one directed against the V3 loop and the other against the CD4-binding site, neutralizes HIV-1 at much lower concentrations than does either of the individual HuMAbs. Mathematical analysis of this effect suggests cooperative neutralization of HIV-1 by the two HuMAbs and demonstrates a high level of synergy, with combination indices (CIs) of 0.07 and 0.16 for 90% neutralization of the MN and SF-2 strains, respectively. The dose reduction indices (DRIs) for each of the two HuMAbs at 99% neutralization range approximately from 10 to 150. A possible mechanism for this synergism is suggested by binding studies with recombinant gp160 of the MN strain; these show enhanced binding of the anti-CD4 binding site HuMAb in the presence of the anti-V3 loop HuMAb. These results demonstrate the advantage of including both V3 loop and CD4-binding site epitopes in a vaccine against HIV-1 and indicate that combinations of HuMAbs against these two sites may be particularly effective in passive immunotherapy against the virus. © 1992, Mary Ann Liebert, Inc. All rights reserved. |
| Keywords: |
human cell; nonhuman; conference paper; binding affinity; models, biological; enzyme linked immunosorbent assay; antibodies, monoclonal; amino acid sequence; immunotherapy; peptide fragments; cell line, transformed; binding sites; cd4 antigen; antigens, cd4; human immunodeficiency virus 1; hiv-1; human monoclonal antibody; epitopes; mathematics; virus neutralization; passive immunization; antibody combining site; hiv envelope protein gp120; neutralization tests; chimpanzee; glycoprotein gp 120; human; support, u.s. gov't, p.h.s.; envelope gene
|
